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Abstract
Peptide presentation by MHC class II is of critical importance to the function of CD4+ T cells. HLA-DM resides in the
endosomal pathway and edits the peptide repertoire of newly synthesized MHC class II molecules before they are
exported to the cell surface. HLA-DM ensures MHC class II molecules bind high affinity peptides by targeting
unstable MHC class II:peptide complexes for peptide exchange. Research over the past decade has implicated the
peptide N-terminus in modulating the ability of HLA-DM to target a given MHC class II:peptide combination. In
particular, attention has been focused on both the hydrogen bonds between MHC class II and peptide, and the
occupancy of the P1 anchor pocket. We sought to solve the crystal structure of a HLA-DR1 molecule containing a
truncated hemagglutinin peptide missing three N-terminal residues compared to the full-length sequence (residues
306–318) to determine the nature of the MHC class II:peptide species that binds HLA-DM. Here we present structural
evidence that HLA-DR1 that is loaded with a peptide truncated to the P1 anchor residue such that it cannot make
select hydrogen bonds with the peptide N-terminus, adopts the same conformation as molecules loaded with full-
length peptide. HLA-DR1:peptide combinations that were unable to engage up to four key hydrogen bonds were also
unable to bind HLA-DM, while those truncated to the P2 residue bound well. These results indicate that the
conformational changes in MHC class II molecules that are recognized by HLA-DM occur after disengagement of the
P1 anchor residue.
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Introduction
Cell surface presentation of antigenic peptides by major
histocompatibility class II (MHCII) molecules to CD4+ T cells
plays a pivotal role in the adaptive immune response to foreign
pathogens. Antigen presenting cells not only present antigen to
T cells, but also provide co-stimulatory signals that reflect the
physiological context in which the antigen was acquired, and
these are important indicators that determine whether tolerance
should be maintained or an immune response initiated [1].
Antigen-specific T cell priming may take many hours within the
lymph node [2] and during this time the peptides presented by
MHCII must remain stably bound. Accordingly, MHCII:peptide
complexes are extremely long-lived with half-lives of days to
weeks [3,4], and empty MHCII molecules rapidly lose their
ability to re-bind peptide [5,6]. While these properties are highly
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desirable in the surface-displayed complex, they represent
significant challenges during intracellular peptide loading, when
facile exchange must occur to support effective selection of the
highest-affinity peptides.
The critical importance of human leukocyte antigen (HLA)-
DM (DM) in the MHCII peptide-loading pathway was first
determined in cells that displayed high levels of class II-
associated invariant chain (CLIP) peptide on surface MHCII [7].
CLIP is a remnant of the invariant chain (a chaperone protein
with which nascent MHCII molecules are folded), which acts to
protect the peptide-binding groove until exchange with peptides
in the endocytic pathway takes place [8,9]. Reconstitution of
this mutant cell line with cDNA encoding DMβ reversed the
defect, and subsequent biochemical assays determined that
DM physically interacts with HLA-DR (DR): CLIP complexes to
promote dissociation of the CLIP peptide [10-12]. Further
studies demonstrated that DM not only acts on MHCII:CLIP
complexes but can promote the exchange of any peptide
[13,14].
DM can act sequentially on many MHC molecules and
because of this it has been proposed that DM has enzyme-like
activity [15,16]. Enzymatic reactions are typically described in
terms of an initial Michaelis complex of enzyme and substrate
that then results in a rearrangement of covalent bonds that
elicits dissociation of a product. DM does not break or form
covalent bonds in the same manner as traditional enzymes but
instead disrupts non-covalent interactions that result in peptide
release from the binding groove of MHCII. Mutations that alter
enzymatic function can often affect the initial formation of the
Michaelis complex or be localized to the active site and affect
catalytic turnover. In an alternative model, DM activity may
instead be described in terms of conformational selection. In
this model, MHCII:peptide complexes exist in multiple
conformational subspecies at equilibrium and the ratio of these
conformers is determined by the properties of the bound
peptide. DM has high affinity for one or more of these
subspecies and by binding to a particular conformer perturbs
the entire equilibrium. The remaining MHCII molecules restore
the equilibrium thus creating more conformers for DM to bind.
This process continues until a new equilibrium with
MHCII:peptide, DM-bound MHCII and free peptide is reached.
The addition of a second free peptide to the system will perturb
the equilibrium in the reverse direction allowing peptide
exchange to occur.
This model of conformational selection is supported by the
crystal structure of the complex between DM and DR [17]
(discussed in more detail below). Superposition of the structure
of free MHCII onto MHCII in complex with DM shows that steric
clashes would prevent free MHCII from binding DM without
prior rearrangement, while DM itself shows very little
rearrangement between free and bound states. Rigidity of the
MHCII molecule also inversely correlates with DM susceptibility
[18]. Introduction of a tyrosine into the P1 pocket by mutation of
DRB1*0101 (DR1) β G86 has been shown to reduce DM
binding, suggesting that DR must be able to adopt a different
conformation to interact productively with DM. In surface
plasmon resonance (SPR) measurements we have tested a
variety of DM and DR mutants and in all cases binding affinity
and catalytic activity have been directly correlated [17,19].
The role of peptide in determining MHC stability and DM
susceptibility has long been appreciated [13,20-22]. The kinetic
stability of peptide: MHC complexes influences DM-mediated
peptide exchange, although the relationship is not strictly linear
[13], implying that some interaction points between peptide and
MHCII are more important than others. MHCII molecules
anchor peptides through a conserved network of hydrogen
bonds and a series of pockets within the peptide-binding
groove [23]. The residue that engages the first pocket defines
the binding register of a given peptide and is called P1. MHCII
pockets typically engage the P1, P4, P6, and P9 residues while
the others are solvent exposed to provide points of contact with
the T-cell receptor (TCR) [23,24]. Residues N-terminal to P1
are referred to as P minus 1 (P-1), P-2 and so forth.
Hydrogen bonds at the peptide N-terminus are thought to be
a deciding factor in DM susceptibility. Stratikos et al. [25],
hypothesized that DM acts to break hydrogen bonds between
DR and the backbone of the peptide and that artificial
complexes that are biochemically unable to form these bonds
would therefore be less responsive to DM. Surprisingly,
complexes missing hydrogen bonds to P-2, P-1 and P1 in fact
had enhanced responsiveness to DM, and thus Stratikos et al.,
concluded that these hydrogen bonds are likely to be broken
before DM interaction rather than after. A number of studies
have focused primarily on the hydrogen bond between the
conserved residue DR1β H81 and the peptide backbone.
Narayan et al. [26], proposed that DM binds to unstable
MHC:peptide complexes and induces conformational changes
that perturb the hydrogen bond supplied by DR1β H81 to eject
peptide from the groove. Results from Zhou et al. [27] and
Ferrante et al. [28], show that DR1β H81 is only part of the
story and that DM activity is not limited to one particular
hydrogen bond, but instead multiple interactions are broken to
facilitate peptide release. SPR measurements [19] have
indicated that the hydrogen bonds reported by Stratikos et al.
[25], at the N-terminus of the peptide and dissociation of the P1
anchor is required before significant quantities of MHCII
molecules adopt the conformational species recognized by DM.
The recent crystal structure of DM in complex with DR1 has
provided new insights into the specific conformational changes
that occur during DM-mediated peptide exchange [17]. DRα
W43, which usually points toward the P1 pocket, adopts a
different orientation when DM is bound and points into the
DM:DR1 interface. Mutational analysis and cross-species
conservation of DRα W43 and the residue it contacts, DMα
N125, suggest that rotation of DRα W43 is a necessary step to
DM engagement. In addition, an extended stretch of random
coil situated above DRαW43 becomes helical, causing a
translation of the aromatic residues DRα F51 and DR1β F89
towards the P1 pocket. These alterations can only occur after
the N-terminus of the peptide has disengaged as hydrogen
bonds between DRα and the peptide backbone are not
compatible with the induced helical content, and DRα F51
occupies the P1 pocket. For these conformational changes to
be reversed, incoming peptide must efficiently engage the P1
pocket to compete with DRα F51 and DR1β F89, regain
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hydrogen bonds to the peptide backbone and rotate DRα W43
back to its normal position.
The structure of the DM:DR1 complex has captured a highly
informative intermediate in the peptide-loading pathway.
However, we cannot deduce from this structure whether the
conformation adopted by MHCII in complex with DM is formed
prior to DM engagement or whether an as yet undescribed
conformation of MHCII is the DM target. To determine the
conformational state of a DM-responsive DR1 molecule prior to
DM engagement, we attempted to solve the structure of DR1
with an N-terminally truncated hemagglutinin (HA) peptide that
was covalently linked into the peptide-binding groove but
missing the P-2, P-1 and P1 residues (pHA*P2-P11; see Table 1
for an explanation of peptide nomenclature). Previous SPR
experiments indicated that this species had high affinity for DM
[19]. Surprisingly, the DR1-peptide complex that crystallized
contained an occupied P1 pocket. This species had apparently
arisen during DR1 loading through preferential binding of a
very minor contaminant in the synthetic peptide preparation
that contained a single amino acid N-terminal extension. Close
inspection of this structure revealed that, despite missing all of
the hydrogen bonds to P-2 and P-1, there were no major
conformational differences compared to the full-length
DR1:pHAP-2-P11 structure [29]. This complex also bound very
poorly to immobilized DM in SPR experiments. We conclude
that P1 anchor disengagement in addition to poor hydrogen
bond occupancy at the peptide N-terminus is required to induce
a conformer of DR1 that can be recognized efficiently by DM.
Results
Crystallization of DR1 carrying a truncated HA peptide
MHCII molecules undergo conformational changes during
peptide exchange [18,22,30], and the recent crystal structure of
a DM:DR1 complex revealed the details of some of these
conformational changes [17]. The critical piece of information
that allowed this structure to be solved was the experimental
evidence that DM binds strongly to DR molecules in which the
P1 pocket is not engaged by peptide [19]. To determine the
Table 1. Peptide abbreviations.
pHA (306-318), pHAP-2-P11 P K Y V K Q N T L K L A T
pHA*P2-P11 V K Q N C L K L A T K-(DNP)
pHA*P1-P11 [P1V] V V K Q N C L K L A T K-(DNP)
pHA*P2-P11 [P2G] G K Q N C L K L A T K-(DNP)
pHA*P-2-P11 P K Y V K Q N C L K L A T K-(DNP)
pHA* P-2-P11 [P1V] P K V V K Q N C L K L A T K-(DNP)
pHA*P1-P11 [P1X] X V K Q N C L K L A T K-(DNP)
pHA*P1-P11 Y V K Q N C L K L A T K-(DNP)
pHAP-2-P11 [P5Alexa] P K Y V K Q C# T L K L A T
Peptides that are linked to DRα via a cysteine at P6 and contain a C-terminal DNP
moiety are indicated with an asterisk. Superscripts denote the residue positions
included in each peptide. Departures from the native pHA sequence are listed in
square brackets. The P1 anchor position of each peptide is underlined. # donates
the presence of maleimide linked Alexa-488.
conformational changes that occur upon release of N-terminal
peptide residues from the MHCII molecule, we examined the
structure of a MHCII molecule loaded with an N-terminally
truncated peptide. DR1 carrying a DRα V65C mutation was
loaded with a truncated version of HA that was missing
residues P-2, P-1 and P1. As removal of the P1 anchor residue
greatly reduces peptide affinity for MHCII, the HA peptide also
carried a cysteine substitution at P6 which allowed covalent
linkage of the peptide into the peptide-binding cleft via DRα
V65C. A dinitrophenol (DNP) moiety on the peptide C-terminus
facilitated purification of DR1 loaded with the truncated HA-
peptide (pHA*P2-P11). This protein crystallized readily and the
structure of the DR1:pHA*P2-P11 was solved by molecular
replacement. The 2.12 Å dataset revealed two molecules in the
asymmetric unit and the structure refined to Rwork and Rfree
values of 19.9 and 23.7% respectively (see Table 2).
We overlaid this structure with other DR1 structures within
the protein database and saw little difference in backbone or
side chain conformations of any residues. We paid close
attention to DRα W43, which undergoes a major rotation in the
crystal structure of DM:DR1, and residues on DRα and DR1β
that flank and support the peptide N-terminus. No significant
variations were seen either in terms of conformation or B-
factors (see Figure 1).
Table 2. Data collection and refinement statistics.
Data collection  
Space group C2221
Resolution (Å) 50.0 - 2.12 (2.16 - 2.12)a
Unit cell dimensions  
a, b, c (Å) 95.81, 111.38, 211.54
α, β, γ (°) 90, 90, 90
Wavelength (Å) 1.0332
No. molecules in asymmetric unit 2
Completeness (%) 94.5 (88.9)
Multiplicity 6.1 (5.9)
Rmerge 0.056 (0.311)
<I/σI)> 28.7 (5.1)
Refinement  
Resolution range (Å) 49.3 - 2.12
No. reflections 58717
Rwork/ Rfree 0.199/0.237
No. protein atoms 6153
No. peptide atoms 175
No. of waters 190
Average B-factor (Å2)  
Protein 26.0
Peptide 33.2
Water 27.0
Geometry  
R.m.s. deviation bonds (Å) 0.008
R.m.s. deviation angles (°) 1.144
Ramachandran plot (%)b 98.8, 1.2, 0.0
a. Values in parentheses are for the highest resolution shell.
b Favored, allowed and disallowed regions of the Ramachandran plot [44].
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Figure 1.  Structural comparison of DR1 carrying truncated and full-length peptide.  (A–D) Overlay of DR1 carrying a
truncated HA peptide variant (pHA*P1-P11 [P1V]) missing N-terminal residues P-2 and P-1 (DRα cyan, DR1β blue, peptide green) and
DR1 carrying full-length HA peptide (pHAP-2-P11, gray, 1DLH). (A) Side view of overlaid DR1 ectodomains. (B) Top view of overlaid
peptide-binding grooves with side chains near the peptide N-terminus shown in stick representation. (C) Close-up view of selected
DRα chain residues shown in stick model near the P1 anchor residue. (D) Close-up view of selected DR1β chain residues shown in
stick model near the P1 anchor.
doi: 10.1371/journal.pone.0069228.g001
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The P1 pocket is occupied in the crystal structure
A peptide contaminant is preferentially bound by
DR1.  Unexpectedly, when the electron density corresponding
to the peptide was examined, significant density in the area of
the P1 pocket was observed (see Figure 2A). The extra density
was continuous with the predicted N-terminus of the peptide
and thus was unlikely to be a solvent component of the mother
liquor. We therefore sought to identify whether the peptide was
covalently modified. Matrix-assisted laser desorption/ionization
– time of flight (MALDI-TOF) analysis of the peptide used to
load DR1 molecules showed a major peak at the correct
theoretical molecular weight and was consistent with the
expected purity of the peptide purchased (at least 80%; see
Figure 2C). We again loaded DR1 molecules with pHA*P2-P11
and purified the complexes by size exclusion, anti-DNP affinity
and anion exchange chromatography. Peptides were then
eluted in the presence of dithiothreitol, purified and analyzed by
MALDI-TOF. This revealed two peaks of roughly the same
intensity; one corresponding to the expected molecular weight
of pHA*P2-P11 (1412 Da) and one that was 99 Daltons larger
(1511 Da) (see Figure 2D). Closer inspection of the spectrum
of free peptide revealed that the 1511 Da peak was present,
but had been greatly enriched during the peptide loading
reaction. We therefore concluded that our synthesized peptide
contained a minor peptide contaminant that had a competitive
advantage in the loading reaction compared to the desired
peptide. The difference in mass between the two peaks
corresponded precisely to one valine residue and a peptide
containing an extra valine at the N-terminus fitted the
calculated density well. Peptide sequencing of the 1511 Da
peak by liquid chromatography-tandem mass spectrometry
also indicated an extra valine at the N-terminus. Analysis of the
protein used for crystallization suggested that approximately
half of the DR1 molecules contained the expected peptide,
while the other half had bound the contaminant, assuming the
two peptides behaved similarly in the MALDI-TOF analysis.
DR1 containing the longer peptide is the complex that
crystallizes.  If DR1 contained a mixture of the two peptides
and both species were incorporated into the crystal, then the
atoms at the P1 pocket should have 50% occupancy. To
determine whether the electron density observed was weaker
than expected, we set the occupancy of the P1 valine residue
at 0.5 and performed three rounds of occupancy refinement in
Phenix [31]. In each case the occupancy reverted back to a
value close to 1. We then isolated crystals of DR1:pHA*P2-P11
and analyzed the peptide present by MALDI-TOF and found
that the molecular weight of the peptide was almost exclusively
1511 Da, with the peak of the desired peptide barely detectable
(see Figure 2E). These results indicated that the longer peptide
was enriched during peptide exchange and subsequently
enriched further during crystallization. We ordered a new
peptide preparation at high purity containing a glycine at P2
(pHA*P2-P11 [P2G]) and formed new DR1:peptide complexes for
crystallography. In contrast to the original protein preparation,
we were unable to obtain crystals from this new protein sample
despite extensive screening.
DRα C-terminus contacts the peptide-binding site of a
neighboring molecule.  DR1 typically crystallizes as a “dimer
of dimers” and the crystal structure presented here is no
exception. However, one contact between molecules in the
crystal is of particular interest. As illustrated in Figure 3A& B,
the flexible C-terminus of the DRα chain in one molecule binds
to the partially empty peptide-binding groove of an adjacent
DR1 molecule. When the structure of DR1 with full-length HA
peptide (pHAP-2-P11) is overlaid with this molecule in the
asymmetric unit, it is apparent that the C-terminus of the
neighboring molecule occupies similar space as the pHAP-2-P11
N-terminus (see Figure 3C). This distinctive intermolecular
contact between adjacent DR1 molecules occupies only one of
the two peptide-binding grooves in the asymmetric unit and is
stabilized by similar hydrogen bonds as the pHAP-2-P11 N-
terminus. DR1β H81, which usually interacts with the peptide
backbone at residue P-1, forms a hydrogen bond to the
neighboring DRα C-terminal carboxyl group. Furthermore, the
side chain of DRα S53 forms a hydrogen bond to the backbone
of the third-to-last residue of the DRα C-terminus (DRα L211).
Root mean square deviation analysis between each DR1
molecule in the asymmetric unit reveals no substantial
deviations in structure between the two molecules (0.4623 Å
Cαatoms 1.0032 Å all atoms), despite these differences in
crystal contacts.
Comparison of the N-terminal hydrogen bond network
with the full-length DR1:HA structure
While we were unable to solve a crystal structure of DR1
without a P1 anchor, we did obtain a crystal structure where
key hydrogen bonds between MHC and the peptide backbone
that have previously been implicated in DM activity [25] were
absent due to the truncation of P-2 and P-1. Removal of
hydrogen bonds from the DRα F51 and DRα S53 main-chain
carbonyls to these residues increased the susceptibility of DR1
to DM-mediated peptide exchange by 6.2-fold [25], but it is
unclear whether this effect was primarily due to disruption of
these hydrogen bonds or to a reduction in global stability at the
peptide N-terminus.
In the full-length DR1:pHAP-2-P11 structure, the carbonyl of
DRα F51 forms a hydrogen bond with the amide nitrogen of
P-2, while the amide nitrogen and side chain hydroxyl of DRα
S53 hydrogen bonds to the carbonyl of P-2 and the DR1β H81
imidazole hydrogen bonds to the P-1 carbonyl [29] (see Figure
4D). Due to the peptide truncation, these hydrogen bonds are
absent in the structure presented here (DR1:pHA*P1-P11 [P1V]) and
DR1β H81 instead forms a hydrogen bond to a water molecule
that bridges DR1β H81 and the peptide N-terminus. The other
three conserved N-terminal hydrogen bonds in this area,
formed by peptide residues P1 and P2 with DR1 residues DRα
S53 and DR1β N82, respectively, are unmodified (compare
Figure 4B and 4D). MHCII residues flanking and forming the P1
pocket exhibit no change in position (see Figure 1).
Comparison of full-length DR1:pHAP-2-P11 and this structure
(DR1:pHA*P1-P11 [P1V]) did not reveal increases in B-factors in the
regions implicated in conformational changes during DM
interaction.
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Figure 2.  Peptide side-product with additional valine at P1 position binds in groove.  (A, B) Observed 2Fo-Fc and Fo-Fc
electron density maps contoured to 1σ and 3σ, respectively, when calculated for; (A) model containing HA variant peptide missing
P-2, P-1 and P1 residues, (B) model of contaminating peptide with additional valine at P1. Peptide residue positions are indicated.
(C, D, E) Mass spectra of synthesized peptide pHA*P2-P11; prior to DR1 binding (C), eluted from DR1 after peptide loading (D) and
after crystallization (E). Masses for peptides missing the P1 residue (VKQNCLKLATK-DNP, 1411.7 Da) and containing an additional
valine at P1 position (VVKQNCLKLATK-DNP, 1510.8 Da) are indicated.
doi: 10.1371/journal.pone.0069228.g002
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Figure 3.  Flexible C-terminus of DR1 molecule binds in partially empty peptide-binding groove of adjacent DR1
molecule.  (A) Two molecules in the crystal lattice are shown depicting a contact formed by DRα (orange) C-terminus of one DR1
molecule binding to the partially empty peptide-binding groove of the other DR1 molecule (cyan/blue). (B) Close-up view of the
interactions between the neighboring DRα C-terminus (orange) and the DR1 peptide-binding groove (DRα cyan, DR1β blue, peptide
green). Hydrogen bonds are displayed as dotted lines. (C) Similar view as (B), but overlaid with DR1 containing full-length HA
peptide (gray). The DRα C-terminus occupies an overlapping space as P-2 and P-1 of the full-length peptide.
doi: 10.1371/journal.pone.0069228.g003
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Figure 4.  Absence of two N-terminal peptide residues (P-2, P-1) causes no major conformational change of peptide-
binding groove.  (A) Top view of peptide-binding groove with pHA*P1-P11 [P1V] linked at αC65 (DRα, ribbon, cyan; DR1β, ribbon, blue;
peptide, stick, green). (B) Close-up view of the peptide N-terminus of the structure shown in (A). Hydrogen bonds between DR1
residues and the peptide N-terminus are shown with dotted lines. A water molecule coordinating a hydrogen bond from DR1β H81
to the peptide N-terminus is shown as a blue sphere. (C) Top view of peptide-binding groove with full-length pHAP-2-P11 (ribbon and
stick, gray; 1DLH). (D) Close-up view of the peptide N-terminus of the structure shown in (C). Hydrogen bonds between DR1
residues and the peptide N-terminus are shown with dotted lines. (E) Superimposition of truncated (green) and full-length (gray)
peptide.
doi: 10.1371/journal.pone.0069228.g004
Removal of P-1 Does Not Alter MHCII Structure
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Breaking the hydrogen bond network extending from
DRα F51 to S53 is not sufficient for DM binding in the
presence of the P1 side chain
As DR molecules missing hydrogen bonds at the peptide N-
terminus are more susceptible to DM [25], we would assume
that the species that crystallized has higher affinity for DM than
DR1 containing full-length peptide, but we could find no
evidence of conformational changes that might be recognized
by DM. To further delineate the contribution of hydrogen bonds
to DM susceptibility, we tested different DR1:peptide
complexes (all covalently stabilized through a cysteine at P6)
for their ability to bind to DM by SPR. First, we loaded two HA
variants that were missing P1 anchors. The first had a valine at
P2 and was identical to the peptide preparation used for our
crystallization trials (pHA*P2-P11). This complex exhibited
measurable binding to DM at 2 µM (Figure 5A, green trace).
From our previous analysis of peptide loading using this
preparation of pHA*P2-P11 (Figure 2D), we predicted that the
resulting complexes would contain a mixture of peptides with
the desired product (pHA*P2-P11) and the N-terminally extended
contaminant (pHA*P1-P11 [P1V]) in approximately equal amounts.
To determine the contribution of the contaminating species to
the binding curves, we loaded DR1 with a pure preparation of
pHA*P1-P11 [P1V]. Mass spectrometry analysis confirmed only
the expected peptide was crosslinked into the binding site (data
not shown). DR1:pHA*P1-P11 [P1V] exhibited almost no binding to
DM when injected at 2 µM (Figure 5A, red trace), indicating
that the binding observed using pHA*P2-P11 (Figure 5A, green
trace) was contributed almost entirely by DR1 containing
peptide without a P1 anchor. We then tested complexes loaded
with peptide containing glycine at P2 (pHA*P2-P11 [P2G]). This
complex exhibited strong binding (Figure 5A, blue trace), again
confirming that DR1 complexes containing an unoccupied P1
pocket are preferred binding partners for DM and that
truncation of P-2 and P-1 is not sufficient to induce strong
binding. Control DR1 complexes loaded with full-length pHA
had no detectable binding to DM when either valine (pHA*P-2-P11
[P1V], Figure 5A, gray trace) or tyrosine (pHA*P-2-P11, Figure 5A,
magenta trace) occupied the P1 position.
We further investigated the role of residues at the P-2 and
P-1 positions by directly comparing different concentrations of
DR1 loaded with either pHA*P1-P11 [P1V] or pHA*P-2-P11 [P1V], both of
which contained valine at position P1 (Figure 5B). While dose-
dependent binding could be measured between DM and DR1
molecules containing pHA*P1-P11 [P1V] (Figure 5B, salmon, pink
and red traces), no binding was observed when P-2 and P-1
residues were present (Figure 5B, grayscale traces). Only at 5-
fold higher concentrations could binding of DR1:pHA*P1-P11 [P1V]
approach the binding capacity of DR1:pHA*P2-P11.
The crystal structure of DR1 presented here indicates that
the amide nitrogen of the P1 anchor makes a hydrogen bond to
the carbonyl oxygen of DRα S53 and that DR1β H81 can
coordinate a water molecule which hydrogen bonds to the
peptide N-terminus. To disrupt these hydrogen bonds in
addition to those involving P-2 and P-1 without vacating the P1
anchor position, we synthesized a peptide with a non-natural
amino acid at the N-terminus that resembles tyrosine but is
missing the N-terminal amine group (pHA*P1-P11 [P1X], See
Figures 5C and 4B). When this species was loaded into DR1
molecules, binding to DM was still undetectable by SPR
(Figure 5C, brown trace). So while hydrogen bonds to the
peptide N-terminus influence the interaction between DR and
DM, these data suggest that the interaction is significantly more
sensitive to the occupancy of the P1 pocket.
Destabilization of the peptide N-terminus is critical for
DM activity
We hypothesized that individual hydrogen bonds at the
peptide N-terminus were less important than global stability of
the peptide N-terminus, which secures the P1 anchor residue
in place. DR1 loaded with full-length pHAP-2-P11 is extremely
stable and highly resistant to DM-mediated peptide exchange.
We tested several DR1 mutants that were designed to
destabilize the peptide N-terminus in different ways in an
established fluorescence polarization (FP) assay that
measures peptide release [32] in the presence or absence of
DM. DR1 was loaded with full-length Alexa-488-labeled HA
peptide (pHAP-2-P11 [P5Alexa]) and dissociation was measured in the
presence of excess unlabeled pHAP-2-P11 by FP (see Figure 6).
As expected, unmodified DR1 (Figure 6, red trace) showed
very little peptide exchange in either the absence (Figure 6A)
or presence (Figure 6B) of 100 nM DM over the time course of
the experiment (~24 hours). DRα S53 and DR1β H81 were
chosen for mutation to alanine as both are able to form
hydrogen bonds via their side-chains to the peptide backbone.
Both mutants retained peptide during the 24-hour time-course
similarly to wild-type DR1 but were more responsive to DM-
mediated peptide release (Figure 6, green and blue traces).
DR1β V85 points towards the P1 pocket and is surface
exposed in our crystal structure. In the previously solved
structure of DR1 with full-length HA peptide [29], DR1β V85 is
shielded from solvent by the HA P-2 residue. We therefore
altered the hydrophilicity and electrochemistry of the P1 pocket
and surrounding area by making separate mutations to serine
(Figure 6, pink traces) and aspartic acid (Figure 6, orange
traces). DR1β V85S was well tolerated and displayed robust
binding to HA peptide in the absence of DM. When DM-
mediated peptide dissociation was measured, however, this
mutant responded more strongly to DM than WT DR1. DR1β
V85D displayed a reduced affinity for peptide, showing
significant peptide loss over 24 hours even in the absence of
DM. This mutant was still sensitive to catalyzed peptide
exchange as addition of DM clearly accelerated peptide
dissociation. Thus, in each case tested here, mutants predicted
to destabilize the peptide N-terminus, whether through removal
of hydrogen bonds or deformation of the P1 pocket, resulted in
enhanced susceptibility to DM-mediated peptide exchange.
Discussion
It is clear from a number of lines of evidence that the peptide
N-terminus is important for whether DM targets DR:peptide
complexes for peptide exchange or not [19,25-27]. Peptides
are stabilized along their entire length by a conserved network
of hydrogen bonds and anchored at strategic points by pockets
within the peptide-binding groove [23], but analyses of these
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Figure 5.  Disrupting interactions between P1 side chain and P1 pocket is crucial for DM binding.  (A–C) SPR binding curves
for DR1 molecules covalently linked to the P6 position of peptides indicated at the right of each graph. Each curve and peptide have
the same color. DR1/peptide complexes (2 µM or indicated concentration) were injected for 5 minutes (pH 5.3, 15 µL/min, 25 °C),
followed by buffer injection for an additional 5 minutes. Overall binding (RU) was calculated by subtracting the background binding
to a flow cell containing DM mutant (R98A, R194A), which is unable to interact with DR from the specific binding from the flow cell
containing wild-type DM.
doi: 10.1371/journal.pone.0069228.g005
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interactions have shown that much of the binding energy
holding a peptide in the groove is mediated by hydrogen bonds
at the peptide N-terminus [33,34] and the P1 anchor residue
[35]. It is perhaps not surprising, then, that the lateral face of
DR with which DM interacts is centered towards the peptide N-
terminus [17,36-38].
Biochemical studies of DM function have demonstrated that
DM promotes the dissociation of peptide, chaperones empty
molecules and edits the peptide repertoire [10-12,39-41]. The
recent crystal structure of DM in complex with DR1 provides a
mechanistic explanation to these functions. Structural
rearrangements in the peptide-binding groove of DR1 in this
co-crystal structure result in DR1’s own residues, specifically
DRα F51 and DR1β F89, occupying the P1 pocket [17]. These
changes hold the groove open and allow free peptides to
sample the groove, and only those that can compete out DRα
F51 and DR1β F89 will bind securely.
What is missing from our knowledge of this critical step in the
peptide-loading pathway of MHC class II is a structural
understanding of the species that DM binds. Binding studies
have indicated that truncation of the peptide N-terminus up to
and including the P1 anchor residue is required to measure a
robust interaction between DM and DR [19]. Biochemical
studies that measure peptide exchange suggest that even
modest changes that interfere with the hydrogen bond network
at the peptide N-terminus are sufficient to sensitize a
DR:peptide complex for DM action [25]. We have solved a
crystal structure of DR1 crosslinked to a truncated peptide that
is incapable of forming hydrogen bonds that have been
implicated in DM sensitization. In this structure, we see no
evidence of conformational changes that might promote an
interaction with DM. Therefore, we must look to an alternative
explanation as to why DM is able to act more efficiently on
MHCII:peptide complexes missing select hydrogen bonds to
the peptide N-terminus than those with more stable peptide-
binding properties.
To further address this conundrum we turned to SPR to
directly measure the affinity of various DR1:peptide complexes
to DM. While crystallography provides a static snapshot of the
most abundant and stable conformation of DR1:peptide in
solution, SPR will only report on species that can bind to DM
and are in significant enough quantities to elicit a signal. When
we measured direct DM binding of the species that crystallized,
DR1:pHA*P1-P11 [P1V], we found a 5-fold reduction in binding
compared to our index complex DR1:pHA*P2-P11. Comparison of
DR1:pHA*P1-P11 [P1V] to other structures that are unable to bind to
DM in the SPR assay (specifically DR1:pHAP-2-P11) revealed no
conformational changes to explain the difference in DM affinity.
The most likely explanation for this binding is that only a small
portion of DR1:pHA*P1-P11 [P1V] is in a DM-responsive
conformation and this conformation is not represented in the
crystal structure. As DR1:pHA*P2-P11 [P2G] had much greater
binding than DR1:pHA*P1-P11[P1V], removal of the P1 anchor
residue results in a higher percentage of the DR1:peptide
complex adopting a DM-responsive conformation.
Proteins are in constant motion and the peptide bound within
the groove is no exception. Even the most stably bound
peptide will sample states of partial binding, although much
less often than peptides with poor stability. Removal of peptide-
stabilizing N-terminal hydrogen bonds will lead to an increase
in sampling of partial binding states (e.g., detachment of the
peptide N-terminus) and provides an explanation for the
Figure 6.  DM-catalyzed peptide release is enhanced by mutations that weaken interactions between the peptide N-
terminus and DR1.  (A, B) DR1β mutants H81A, V85S and V85D and DRα mutant S53A were compared with wild type DR1
complexes in peptide dissociation assays. Dissociation at pH 5.3 and 25 oC of Alexa-488-labeled full-length pHAP-2-P11 [P5Alexa] peptide
from preloaded DR1 complexes (100 nM) in the presence of 50 µM unlabeled pHAP-2-P11 competitor peptide was measured by FP.
Dissociation curves were preformed in the absence (A) or presence (B) of 100 nM DM. FP values are presented in millipolarization
units (mP).
doi: 10.1371/journal.pone.0069228.g006
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observation that removal of N-terminal hydrogen bonds are
sufficient to sensitize complexes for DM action. To investigate
whether this might be the case, we used a peptide dissociation
assay to determine if any destabilizing changes at the peptide
N-terminus would increase susceptibility to DM. While
crystallography and SPR primarily measure the most abundant
conformers in solution, this irreversible kinetic assay (unlabeled
peptide is in excess) performed over long time periods is
sensitive to even tiny populations of DM-sensitive DR1
conformers, provided conformational exchange between states
is possible during the time course of the experiment. In these
experiments we did not covalently link peptide in the binding
groove, but instead measured the effect of DR1 mutations near
the peptide N-terminus. We mutated DRα S53 and DR1β H81,
which each contribute a hydrogen bond to the peptide N-
terminus from their respective side chains and changed the
electrostatics of the P1 pocket by mutating the buried DR1β
V85 residue. In each case DM had a greater activity on
destabilized complexes compared with the index complex
DR1:pHAP-2-P11. Furthermore, if movement of the peptide N-
terminus is restricted by introduction of a tyrosine at P1, which
has greater complementarity to the P1 pocket than valine, we
would expect that DM binding would be reduced, and this was
also found to be the case. In addition, other methods to
stabilize the peptide N-terminus including inclusion of P-1 and
P-2 residues, which can engage conserved hydrogen bonds to
the DR1 residues lining the peptide-binding site also reduced
DM binding. Thus we conclude that disengagement of
hydrogen bonds at the peptide N-terminus is not sufficient to
induce bulk conformational changes that allow DM binding, but
rather act to increase the likelihood of P1 anchor
disengagement.
It is typically difficult to crystallize proteins that are
conformationally heterogeneous, however conformational
heterogeneity can sometimes be captured. Painter et al,
recently reported the crystal structure of DR1 carrying a
mutation in DRα F54 near the P1 pocket [34]. The DM:DR
structure [17] shows that this residue undergoes a significant
conformational change during peptide exchange and rotates up
and out of the P1 pocket to become solvent exposed. One of
the molecules in the asymmetric unit of the DRα F54C
structure, displays an altered conformation of residues near the
peptide N-terminus, reminiscent of the more substantial
conformational changes seen in the DM:DR structure. The
structure of DRα F54C clearly captures one of the
conformational intermediates that MHC molecules constantly
sample, although DRα W43 remained in place, indicating
further conformational changes are required to bind DM.
The crystal structure of DR1 containing peptide without a P1
anchor remains an important and challenging structural target
for understanding DM-mediated peptide exchange, but
successful crystallization will require a strategy that addresses
a number of hurdles. We found that the P1 pocket has such a
strong preference to be filled that contaminating peptide
sequences with poor P1 anchors will be selectively bound if
available during the loading reaction. In addition, flexible
polypeptide stretches in the DR1 molecules themselves may
occupy the peptide-binding groove during crystallization, as
observed in one (but not both) of the molecules of the
asymmetric unit in the structure presented here. Selective
crystallization of the species of DR1 carrying a peptide with a
P1 anchor may indicate that partially empty molecules have
increased structurally heterogeneity. While the step-wise
conformational changes of peptide exchange remain to be fully
elucidated, the work presented here indicates that breaking the
hydrogen bond network at the peptide N-terminus does not in
itself elicit a conformational change in the bulk of DR1:peptide
complexes in solution.
Materials and Methods
Peptides
The peptide (pHA*P2-P11; see Table 1) used for crystallization
studies had the sequence VKQNCLKLATK(DNP), where
K(DNP) is a lysine residue derivatized with DNP and was
provided at a purity of 80.13% (Peptide 2.0, Chantilly, VA,
USA). The following peptides used in SPR experiments (which
have the P1 anchor underlined) were purchased from 21st
Century Biochemicals, Marlboro, MA, USA and had these
sequences (purity): pHA*P2-P11 [P2G], GKQNCLKLATK(DNP)
(94.25%), pHA*P1-P11 [P1V], VVKQNCLKLATK(DNP) (75.70%),
pHA*P-2-P11 [P1V], PKVVKQNCLKLATK(DNP) (74.83%), pHA*P1-P11
[P1X], XVKQNCLKLATK(DNP) (75.15%, where X is 4-
hydroxyphenylpropionic acid), The remaining peptides were
purchased from Peptide 2.0, Chantilly, VA, USA. pHA*P-2-11,
PKYVKQNCLKLATK(DNP) (86.68%), pHA*P1-P11,
YVKQNCLKLATK(DNP) (86.55%). FP experiments utilized
pHAP-2-P11[P5Alexa] PKYVKQC(Alexa-488) TLKLAT, where
C(Alexa-488) is a cysteine residue conjugated to Alexa-488 via
a maleimide linkage. This peptide and its unlabeled counterpart
pHAP-2-P11 PKYVKQNTLKLAT were also ordered from Peptide
2.0 (Chantilly, VA, USA).
DR1 production and purification
The ectodomain of DR1 was expressed in baculovirus
infected Sf9 (Spodoptera frugiperda) insect cells. FOS and
JUN were fused to the respective DRα and DR1β C-termini to
facilitate folding during expression. Low-affinity CLIP peptide
(CLIPlow, SKARMATGALAQA; substituted anchor residues are
underlined) was fused to the DR1β N-terminus via a 13 amino-
acid flexible linker containing an endoproteinase GluC protease
cleavage site. Mutants were created by site-directed
mutagenesis using a QuikChange Lightning site-directed
mutagenesis kit (Agilent Technologies). Protein was harvested
from Sf9 culture media 3 days after infection with baculovirus
and was purified by affinity chromatography with a monoclonal
antibody to DR (L243; American Type Culture Collection).
Protein was eluted from L243 conjugated sepharose using 50
mM CAPS pH 11.5 and neutralized with the addition of sodium
phosphate buffer pH 6.0. Aggregated material was removed by
gel filtration (Superose 6, GE Healthcare). The covalently
linked CLIPlow peptide and C-terminal leucine zippers were
cleaved with GluC containing a His-tag (New England BioLabs
Inc.). The protease was removed with Ni2+-NTA beads (Sigma-
Aldrich) and protein was further purified by anion exchange
chromatography (MonoQ, GE Healthcare). Using the small
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molecule J10 [32] to promote peptide exchange, cleaved
CLIPlow peptide was exchanged for HA peptide variants labeled
with DNP via a lysine side chain at the peptide C-terminus and
containing a P6 cysteine (21st Century Biochemicals, Marlboro,
MA, USA; Peptide 2.0, Chantilly, VA, USA). Covalent
attachment of the peptide to the cysteine introduced at position
65 of DRα chain, was performed at pH 8.0 in redox conditions
using a mixture of oxidized and reduced glutathione as
described previously [19]. The complex was further purified by
gel filtration to remove free peptide, anti-DNP affinity
chromatography to isolate complexes with the loaded peptide
and anion exchange chromatography (MonoQ, GE
Healthcare).
DM was also expressed in baculovirus infected Sf9 cells as
previously described [19]. Briefly, soluble DM proteins carrying
a C-terminal BirA tag (GLNDIFEAQKIEWHE) on DMα and a C-
terminal protein C tag (EDQVDPRLIDGK) on DMβ were
expressed in Sf9 insect cells and purified by anti-Protein C
affinity chromatography (Roche Applied Science). DM was
bound to anti-Protein C agarose in the presence of 2 mM Ca2+
and eluted in Tris buffered saline containing 5 mM EDTA. DM
was enzymatically biotinylated at the BirA tag using biotin
ligase and finally purified by gel filtration (Superose 6, GE
Healthcare).
Crystallization, Data Collection and Structure
Determination
For crystallization, purified DR1:pHA*P2-P11 was dialyzed
against 10 mM MES buffer (pH 6) and concentrated to ~10
mg/mL. Initial screening plates were set up at the Collaborative
Crystallization Center in Melbourne, Australia, using the nano-
dispensing crystallization robots Mosquito Crystal (TTP
LabTech) and Phoenix (Rigaku). Final crystals of DR1:pHA*P2-
P11 were grown in 100 mM sodium acetate (pH 4.3), 9% PEG
10,000 at 20 °C using hanging drop vapor diffusion. Crystals
were mounted using MicroLoops E (Mitegen) and transferred
into precipitant solution supplemented with 38% (v/v) ethylene
glycol and flash frozen in liquid nitrogen. X-ray diffraction data
were collected at 100 K at beamline 23-ID–D of the General
Medicine and Cancer Institutes Collaborative Access Team
(GM/CA-CAT) at the Advanced Photon Source (Argonne
National Laboratory, IL, USA) performing a continuous vector
scan over the crystal. Crystals diffracted up to 2.12 Å and
diffraction data were collected from a single crystal at a
wavelength of 1.0332 Å using a CCD detector (MARmosaic
300). Data were indexed and scaled using the software
HKL2000 [42]. Statistics are reported in Table 2. The structure
of DR1 with the truncated HA peptide was solved by molecular
replacement with Phaser [43] using the previously solved
DR1:pHAP-2-P11 structure (PDB entry code 1DLH) [29] as the
search model. The structure was refined using Phenix [31] and
evaluation of the structure was carried out with MolProbity [44].
During refinement manual adjustments of the structure were
performed using the software Coot [45]. To assess the
accuracy of the crystal structure the statistical quantities Rfree
and Rwork were used [46]. For occupancy refinement the
occupancy of Val at P1 position was set to 0.5 and 3 rounds of
occupancy refinement in Phenix were performed. The
coordinates and structure factors have been deposited in the
Protein Data Bank (entry code 4I5B). Figures depicting protein
structures are generated with PyMOL (Schrodinger).
Surface Plasmon Resonance
SPR experiments were conducted on a BIAcore 3000
machine (GE Healthcare) using streptavidin chips (GE
Healthcare), which were primed and normalized before
immobilization of biotinylated protein. For immobilization
biotinylated wild-type DM and mutant DM (αR98A, αR194A;
DM mut) were separately injected in two consecutive flow cells
after diluting the protein to a concentration of 0.5 mg/mL in
HBS-EP buffer (GE Healthcare). 500 RU (response units) of
protein were immobilized in each flow cell using a flow rate of
10 µL/min at 25 °C. Experiments were carried out in degassed
50 mM citrate phosphate buffer (pH 5.3), 150 mM NaCl and
0.06% C12E9 detergent (Calbiochem; EMD Chemicals).
DR:peptide complexes (analyte) were diluted into the running
buffer before injection and injected at 2 µM or the indicated
concentration followed by buffer (15 µL/min, 25 °C). Chips were
regenerated by injection of pHAP-2-P11 (50 µM). Binding of the
reference flow cell (DM mut) was subtracted from binding in the
flow cell of DM wt.
Peptide binding assay
For FP experiments cleaved DR1:CLIPlow was incubated with
pHAP-2-P11 [P5Alexa] labeled at position P5 (lysine-to-cysteine
substitution) with a maleimide derivative of Alexa-488
(Molecular Probes). Excess peptide was separated by gel
filtration using Bio-Spin 30 Tris columns (Bio-Rad
Laboratories). FP experiments were conducted on a Victor3 V
multilabel plate reader (PerkinElmer) using black polystyrene
384-well flat-bottomed plates (Corning). DR1:pHAP-2-P11 [P5Alexa]
complexes (100 nM) were incubated with a molar excess (50
µM) of unlabeled pHAP-2-P11 in the absence and presence of DM
(100 nM). Measurements were performed in triplicates in a
volume of 40 µL in 50 mM citrate phosphate buffer (pH 5.3)
containing 150 mM NaCl at 25 °C.
Mass Spectrometry
To release covalently linked peptide from DR1 (20 µg) for
analysis by mass spectrometry, the complex was incubated for
30 minutes at 25 °C in the presence of 4 mM dithiothreitol. After
addition of 20-fold molar excess of unlabeled pHAP-2-P11, the
complex was incubated for an additional hour. Free DNP-
labeled peptide was separated by anti-DNP chromatography
and lyophilized. To analyze the peptide bound to DR1 in the
crystal, DTT (40 mM) was added to isolated crystals and
incubated over night at 25 °C. Samples were submitted to the
Dana-Farber Cancer Institute Molecular Biology Core Facility
for MALDI-TOF analysis and liquid chromatography-tandem
mass spectroscopy analysis.
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